49results about How to "Has antitumor effect" patented technology

The invention discloses a mixed type liquid cigarette and a manufacturing method and the application. The mixed type liquid cigarette is made of materials consisting of tobacco leaf and/or tobacco pole, angelica, radix codonopsitis, astragalus, steroid, schisandra, scutellaria barbata, rhizome imperatae, fritillaria thunbergii, cinnamon, costus root and jujube. When people have the mixted type liquid cigarette of the invention, the cigarette does not need to be burned and does not produce tar and other carcinogenic substances. The cigarette not only has the natural fragrance flavor but also excites nervus centralis, relieves organic fatigue and anxiety, improves the respiratory system situation( for example, relieving cough, eliminating phlegm and relieving asthma), strengthens the organic immunological competence, and has antineoplastic effects. Therefore, the mixed type liquid cigarette serves as health care cigarette or medical cigarette and is used for human body health care or treatment.

The invention relates to application of protosappanin B, in particular to application of a 0.2 to 2.4 percent protosappanin B solution in preparation of bladder cancer resistant perfusion fluid. For filling up the research blank of the protosappanin B at home and abroad, the invention provides new application of the protosappanin B. Human bladder cancer cell strains T24 or mouse bladder cancer cell strains BTT are inoculated to mouse bodies to form bladder cancer, and the mice are grouped and respectively subjected to experiments with injection water, mitomycin and the protosappanin B; experiment results show that the lives of the mice injected with the mitomycin and the protosappanin B are prolonged, the tumor weight is reduced, and a tumor inhibiting effect is achieved; and the protosappanin B has a remarkable bladder cancer inhibiting effect, and can be widely applied to preparation of the bladder cancer resistant perfusion fluid.

The invention relates to a medicine and food dual-purpose traditional Chinese medicine composition with anti-tumor activity and immunoregulation effect and application thereof. The composition comprises ganoderma lucidum extract and radix astragali extract in mass ratio of 1:0.5-3, wherein the ganoderma lucidum extract comprises the following effective medicinal ingredients in percentage by weight: 50-70% of ganoderma lucidum polysaccharides and 6-10% of ganoderma lucidum total triterpene; and the radix astragali extract comprises the effective medicinal ingredient in percentage by weight: 20-45% of radix astragali polysaccharide. Based on traditional Chinese medicine pharmacological animal experiments, the composition of the invention is found having anti-tumor effect, improves the immunocompetence of a body, and has a medicine and food dual-purpose property. In addition, compared with single ganoderma lucidum, the use of the radix astragali as raw material reduces the cost of the traditional Chinese medicine composition, the anti-tumor and immunoregulation curative effects are close to the curative effects of the same amount of the single ganoderma lucidum, and the invention has certain economic value.

The invention discloses an andrographolide derivative and a preparation method and application thereof. The derivative has a structure expressed by the formula (1), wherein R1 is C1 to C11 chain hydrocarbon or C1 to C11 chain hydrocarbon with terminals substituted by ternary to heptabasic ring groups; and R2 and R3 are hydrogen, organic acid radical, inorganic acid radical, alkyl or acryl. The andrographolide derivative can be made into tablets, capsules, granules, fine granules, powder, pills, patches, oral liquid or injection.

The invention relates to a construction method and applications of targeting oncolytic-adenovirus carier Ad-TD-gene. The carrier of the oncolytic-adenouirus is Ad5, the adenovirus-5 in Subcategory C;three internal genes of the adenovirus, including E1A-CR2, E1B19K and E3gp-19K, are deleted; an E3B gene is retained, and an E3gp-19K promoter expression exogenous therapeutic gene is retained; and any antigen gene which is helpful to treating tumors or used for infectious disease vaccines can be inserted into the carrier. The Ad-TD-gene has the advantages of specificity, high safety and high efficiency, can carry various antigen genes treating tumors, and can be used for treating various solid tumors. By utilizing the human chemotactic factor CCL 21 gene as the therapeutic gene, the Ad-TD-hccL21 has the effects of tumor targeting and tumor resistance, lays foundation for introducing targeting genetic engineering medicines towards clinical applications, and provides an effective therapy for patients with tumors.

The invention discloses a method for preparing an anti-bacterial and anti-cancer titanium dioxide nanotube from an iridium complex. The method comprises steps as follows: 1), the iridium complex is acquired; 2), the iridium complex is dissolved in ethyl alcohol; 3), the titanium dioxide nanotube is soaked in an iridium complex solution, nitrogen is introduced and microwave processing is performed; 3), the solution is left to stand and cooled to the normal temperature, then the solution is pressurized to 20-25 Mpa, keeps the pressure for 2-3 min and then is depressurized to normal pressure, and centrifugation is performed for 30-60 min; 4), a liquid supernatant after centrifugation is removed, a lower solution and solids are taken and placed in an environment at the temperature of 100-120 DEG C, are pressurized to 20-25 Mpa, keep the pressure for 2-3 min and then are depressurized to the normal pressure, and drying is performed for 20-26 h. With the adoption of the method, anti-bacterial and anti-cancer capacity of the titanium dioxide nanotube is high, growth of harmful cells can be persistently and effectively inhibited, the titanium dioxide nanotube particularly has more remarkable resisting effect on bone cancer, and the medical utilization effect of the titanium dioxide nanotube can be effectively improved.

The invention relates to recovery aid granules containing hoantchy root and semen coicis. A preparation method comprises the following steps: taking 10 gouts of raw materials such as hoantchy root, ginseng, semen coicis, tuckahoe, Actinidia valvata Dunn, barbed skullcap herb, paris rhizome, oldenlandia diffusa, licorice and Chinese jujube according to a definite proportion; then crushing the semen coicis from the 10 gouts of the raw materials into meal, adding petroleum ether into the meal by 1 to 3 times (in terms of weight proportion) of the amount of the semen coicis, heating and reflowing the mixture for 0.8 to 1.2 hours at a temperature of between 60 and 90 DEG C, filtering the mixture twice, mixing the extracts, and reclaiming the petroleum ether to obtain semen coicis oil; after the extraction, adding 8 to 12 times of water into the semen coicis and the rest nine gouts of the raw materials, stirring and boiling the mixture for 0.8 to 1.2 hours, filtering the extract, and condensing the extract to have a relative density of 1.15 to 1.22 g/cm; and adding the semen coicis oil and stevioside into the condensed extract, evenly mixing the mixture, spraying and drying the mixture, adding dextrin into the solid, and drying the mixture to prepare the granules. The recovery aid granules are prepared by refining, extracting and scientifically processing the pure traditional Chinese medicine, and have the efficacies of eliminating pathogens and strengthening healthy energy, tonifying qi and nourishing the blood.

The invention discloses a low-toxicity Pt complex, and belongs to the technical field of anticancer chemical drugs. The structure of the complex is as shown in a general formula (1) or a general formula (2), pterostilbene is introduced into the platinum (IV) complex, and the anti-tumor effect of the platinum complex is improved and the toxic and side effects of the platinum complex on normal cells are reduced by utilizing the anti-inflammatory and anti-oxidation double functions of the pterostilbene.

The invention belongs to the fields of medicinal chemistry and pharmacotherapeutics, and discloses a quinolone derivative as shown in a formula I in the description or pharmaceutically acceptable salt or ester thereof. The invention also discloses application of the quinolone derivative or the pharmaceutically acceptable salt or ester thereof in preparation of an STAT3 inhibitor or in preparation of a medicine for preventing and/or treating tumor-related diseases. Pharmacological experiments prove that the quinolone derivative or the pharmaceutically acceptable salt or ester thereof can achieve the anti-tumor purpose by inhibiting proliferation of tumor cells and inducing apoptosis of the tumor cells, and the quinolone derivative or the pharmaceutically acceptable salt or ester thereof has an anti-tumor effect and is relatively low in toxicity. The quinolone derivative can be combined with a target protein STAT3SH2 structural domain, so that formation of an STAT3 homodimer is mediated, and a JAK-STAT3 cellular pathway is selectively inhibited.

The invention discloses a preparation method for separating and extracting a new compound from an A. terreus secondary metabolite. The method comprises the steps of spore preparation, strain fermentation, extraction on the secondary metabolite, and separation and purification, specifically, an epigenetic modifying regulator TSA, nicotinamide and dipeptide are added into a fungal culture medium, fermentation culture is carried out, a fermentation broth and mycelia are subjected to separate extraction, and a fermentation concentrate is separated and purified by column chromatography and high performance liquid chromatography to obtain the separated and extracted new compound. The beneficial effects are as follows: the nicotinamide and dipeptide are added into the culture medium and produce asynergistic gain effect with the epigenetic modifying regulator TSA, and epigenetic modification is performed on A. terreus OUCMDZ-2739 to effectively activate the expression of the silencing gene ofthe strain, and obtain a new secondary metabolite through separation; the novel compound prepared by the invention has a good anti-tumor effect.

The invention provides a drug for inhibiting brain tumor and application thereof. The drug for inhibiting the brain tumor comprises at least one TRPV4 agonist capable of promoting calcium ion internalflow of a TRPV4 signal channel. The drug has a good treatment effect on brain tumors and related diseases thereof, and has a good application prospect in treatment of brain tumors and related diseases thereof. The drug is applied to medicines for treating brain tumors and related diseases thereof, can reduce toxic and side effects generated in the clinical treatment process of the brain tumors and the related diseases thereof and improve the treatment effect of the brain tumors and the related diseases thereof.